"It's an honour for Theratechnologies to receive this prestigious prize", said Yves Rosconi, the Company's President and Chief Executive Officer.  "As genuine recognition by our peers, this prize pays tribute to the work and dedication of a team that was able to successfully complete a clinical program for tesamorelin, a molecule discovered in-house, file for marketing approval with the American regulatory authorities and join forces with an ideal partner for its commercialization in the United States", he added.  "I would like to thank all of Theratechnologies' employees who, through their efforts, contributed to the achievement of our business-plan objectives, as well as our shareholders for their loyal support and patience", Mr. Rosconi concluded.

Awarded by the Fondation Armand-Frappier on the recommendation of its scientific committee, Le Prix Santé recognizes success by Québec companies in the human health, animal health, environmental and agro-food fields.  In order to qualify, companies must have conceived, developed and commercialized a scientific innovation, or be about to do so.

In 1998, Theratechnologies received Le Prix Émergence from the Fondation Armand-Frappier in recognition of its notable contribution to research and development in Québec.

About the Fondation Armand-Frappier
The Fondation Armand-Frappier is a non-profit organization that encourages excellence in the training of the next generation of scientists and the advancement of health research in its areas of interest.  Since its inception in 1978, the Fondation has distributed more than $8 million in the form of scholarships, research chairs, equipment purchases or contributions to scientific projects.  The Fête Champêtre, a true celebration of healthcare research, is the high point of its fund-raising activities and is considered a not-to-be-missed occasion by the business and life-science milieus. 

About Theratechnologies
Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the growth hormone releasing factor.

In 2008, Theratechnologies completed its Phase 3 clinical program evaluating tesamorelin in treating excess abdominal fat in HIV patients with lipodystrophy and signed a collaboration and licensing agreement with EMD Serono, Inc., for the commercialization of tesamorelin in the United States.

With a New Drug Application recently filed with the US authorities, Theratechnologies' growth strategy is firmly focused on the development of tesamorelin, in the United States and in other potential lipodystrophy markets, as well as through additional clinical programs.

The Company refers potential investors to the "Risks and Uncertainties" section of its Annual Information Form (the "AIF") dated February 24, 2009. The AIF is available at http:/www.sedar.com/ under the Company's public filings. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements.

Forward-looking information reflects current expectations regarding future events and speaks only as of the date of this press release and represents the Company's expectations as of that date. The Company does not undertake to update or amend such forward-looking information whether as a result of new information, future events or otherwise, except as may be required by applicable law.

In 2008, Theratechnologies completed its Phase 3 clinical program evaluating tesamorelin in treating excess abdominal fat in HIV patients with lipodystrophy. The Company has also entered into a collaboration and licensing agreement with EMD Serono, Inc., for the commercialization of tesamorelin in the United States.

Theratechnologies' growth strategy is firmly focused on the development and exploitation of tesamorelin, in the United States and in other potential lipodystrophy markets, as well as through additional clinical programs.

Forward-Looking Information
This press release contains information or statements that are considered "forward-looking information" within the meaning of applicable securities legislation. This forward-looking information includes, but is not limited to: information regarding the approval by the FDA of tesamorelin as a therapeutic product, the beneficial nature of tesamorelin for patients, the commercialization of tesamorelin and its success for the treatment of HIV-associated lipodystrophy. Words such as "will", "may", "could", "should", "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or variations of them denote forward-looking information.

Forward-looking information is based upon a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company's control, which could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These risks and uncertainties include, but are not limited to: the risk that the FDA does not accept the NDA filing and, even if accepted, does not approve tesamorelin for the treatment of excess abdominal fat in HIV patients with lipodystrophy, the risk that the results from the treatment with tesamorelin varies from one patient to another and the risk that the Company may not be able to commercialize its tesamorelin in other potential lipodystrophy markets.

The Company refers potential investors to the "Risk and Uncertainties" section of the Company's Annual Information Form (the "AIF") dated February 24, 2009. The AIF is available at http://www.sedar.com/ under the Company's public filings. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements.

Forward-looking information reflects current expectations regarding future events only as of the date of release of this press release and represents the Company's expectations as of that date. The Company does not undertake to update or amend such forward-looking information whether as a result of new information, future events or otherwise, except as may be required by applicable law.

BioFinance is the Canadian Life Science industry's leading investor conference that brings together key industry players to consider investment opportunities and issues affecting companies in biotechnology.

About Theratechnologies
Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the growth hormone releasing factor. Theratechnologies recently completed two Phase 3 clinical trials evaluating tesamorelin in treating excess abdominal fat in HIV patients with lipodystrophy and signed a collaboration and licensing agreement with EMD Serono, Inc., for the commercialization of tesamorelin in the United States. With a regulatory filing to be submitted to US authorities shortly, Theratechnologies' growth strategy is firmly focused on the development and exploitation of tesamorelin in the United States and in other potential lipodystrophy markets, as well as through additional clinical programs.

Oral Presentation
Dr. Julian Falutz, Director of the HIV Metabolic Clinic at Montreal General Hospital, Assistant Professor at McGill University Medical School, and Lead Investigator for tesamorelin trials in Canada, presented pooled analysis results from the main phase of the Company's two Phase 3 clinical trials. The results indicated that after 26 weeks of treatment (each trial was extended to 52 weeks), the 543 patients treated with 2 mg daily of tesamorelin experienced reduction of visceral adipose tissue ("VAT"), preservation of subcutaneous adipose tissue ("SAT"), and an improvement in triglycerides, without significant changes in glucose parameters.

At Week 26, VAT decreased significantly in tesamorelin-treated patients (-13.1 vs. 2.3%, tesamorelin vs. placebo, p<0.001), while no clinically significant changes were observed in limb fat by DEXA (0.2 vs. 3.0%, tesamorelin vs. placebo, p=0.001). No significant changes were observed in SAT (0.8 vs. 1.3%, tesamorelin vs. placebo, p=0.08). Treatment with tesamorelin was associated with a significant decrease in triglycerides (-0.4 vs. 0.1mmol/L, tesamorelin vs. placebo, p<0.001). Mean IGF-I levels increased within physiological range in tesamorelin-treated patients (83.4%, p<0.001 vs. placebo). No significant differences were observed between groups in fasting glucose and insulin as well as the 2-hour oral glucose tolerance test.

Poster Presentation
The poster described the results of two randomized, open-label, two-way crossover studies evaluating the impact of tesamorelin on the pharmacokinetics of Simvastatin and Ritonavir in healthy subjects. Simvastatin and Ritonavir are two drugs that could potentially be administered together with tesamorelin. These studies showed that the impact of tesamorelin on CYP3A activity appears to be minimal. Either medication may be co-administered with tesamorelin without changing their dosing regimen.

In these two studies, subjects were administered 2 mg tesamorelin on Days 1 to 7, with 80 mg simvastatin (n=58) or 100 mg ritonavir (n=32) co-administered on Day 6 (Treatment A), or a single dose of simvastatin or ritonavir alone on Day 6 (Treatment B) in a crossover manner. PK samples collected on Day 6, measured simvastatin, ritonavir and tesamorelin plasma concentrations.

For simvastatin, ratios of least squares geometric means and corresponding 90% CIs for AUC0-t, AUC0-inf and C_max were contained within the acceptance range. For the metabolite simvastatin acid, only the lower CI for AUC_0-inf (78.6%) was slightly outside of the range. For ritonavir, ratios and 90% CIs for AUCs were contained within the acceptance range, but for Cmax, the lower CI was 74.8%, suggesting a slight difference in the maximal concentration of ritonavir in the presence of tesamorelin administration However, since the observed A/B ratios for AUCs and C_max parameters for rinotavir were approximately 90%, these minor decreases indicated that no dose adjustment of ritonavir is required in the presence of tesamorelin.

The poster presented is now available on Theratechnologies' website at http://www.theratech.com/

About HIV-Associated Lipodystrophy
Several factors including the antiretroviral drug regimen and the virus itself are thought to contribute to HIV-associated lipodystrophy, which is characterized by body composition changes, dyslipidemia and glucose intolerance. The changes in body composition include excess abdominal fat accumulation. There is currently no approved treatment available for the excess abdominal fat related to HIV-associated lipodystrophy, a condition that can stigmatize patients and discourage HIV treatment adherence.

About Theratechnologies
Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the growth hormone releasing factor. Theratechnologies recently completed two Phase 3 clinical trials evaluating tesamorelin in treating excess abdominal fat in HIV patients with lipodystrophy and signed a collaboration and licensing agreement with EMD Serono, Inc., for the commercialization of tesamorelin in the United States. With a regulatory filing to be submitted to US authorities shortly, Theratechnologies' growth strategy is firmly focused on the development and exploitation of tesamorelin in the United States and in other potential lipodystrophy markets, as well as through additional clinical programs.

Forward-Looking Information
This press release contains certain statements that are considered "forward-looking information" within the meaning of applicable securities legislation. This forward-looking information includes, but is not limited to: information regarding submission of a regulatory file with US regulatory agencies. Words such as "will", "may", "could", "should", "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or the variations of them denote forward-looking information.

Forward-looking information is based upon a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company's control, that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These risks and uncertainties include, but are not limited to: a delay in submitting the regulatory file to US regulatory authorities. The Company refers potential investors to the "Risks and Uncertainties" section of its Annual Information Form (the "AIF") dated February 24, 2009. The AIF is available at http:/www.sedar.com/ under the Company's public filings. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements.

• The Company's lead product, tesamorelin, met established clinical objectives
• Collaboration and licensing agreement with EMD Serono to commercialize tesamorelin
• Business plan for the next three years to focus on the development and exploitation of tesamorelin

Montréal, March 26, 2009 - Speaking to shareholders who gathered in Montréal today for the annual and special meeting of Theratechnologies, Mr. Paul Pommier, Chairman of the Board, said that the Company could look to the future with confidence. He first stated that the Company had completed the Phase 3 confirmatory clinical trial of its lead product, tesamorelin, successfully and on schedule, adding that "the success of this clinical trial is concrete evidence of tesamorelin's value and of its potential to become a beneficial therapy for patients and an important commercial success."

Mr. Pommier continued by highlighting the collaboration and licensing agreement reached with EMD Serono, an affiliate of the pharmaceutical company Merck KgaA. "This agreement, which is the fruit of a strategic review that we conducted during 2008, represents an uncommon achievement," said Mr. Pommier. "The agreement enables Theratechnologies to join forces with an ideal partner for the commercialization of tesamorelin in the US market. EMD Serono has all the qualities that we were looking for in a partner, notably solid sales and marketing capabilities within the HIV patient population," he added.

Moreover, Mr. Pommier pointed out that despite a very difficult economic situation in all sectors of the economy and most particularly in the biotech sector, Theratechnologies enjoys a solid financial position.

Following Mr. Pommier's remarks, Mr. Yves Rosconi, President and Chief Executive Officer of Theratechnologies, reiterated that the Company's growth strategy for the next three years will be tightly focused on the development and the exploitation of tesamorelin. "Our convincing clinical results enable us to concentrate on our priority which is to prepare and submit a New Drug Application ("NDA") to the Food and Drug Administration ("FDA") in the United States. We are currently completing the submission, which will be delivered to the FDA before the end of June," Mr. Rosconi stated.

"In keeping with our business plan, we will explore possibilities for tesamorelin in other potential markets such as Europe, Latin America, and Canada. Because our expertise is currently in the discovery and the development of peptides and not in commercialization, the best way for Theratechnologies to develop new markets is through partnerships," Mr. Rosconi said.

Mr. Rosconi added that the development of additional clinical programs for tesamorelin in other indications presents new growth possibilities for the Company. Amongst these he mentioned wasting associated with pulmonary diseases, and abdominal obesity associated with growth hormone deficiency.

Theratechnologies' Senior Executive Vice-President and Chief Financial Officer, Mr. Luc Tanguay, painted a very favourable picture of the Company's financial position. Commenting on results made public a day earlier, Mr. Tanguay said that Theratechnologies had completed the first quarter of 2009 with $72 million in liquidities and downward trending expenses. He added that this situation was due mainly to the payment received at the closing of the agreement with EMD Serono and by lower research and development costs. "Theratechnologies today benefits not only from its relationship with a partner of choice but also from a particularly enviable balance sheet and financial position, given the present economic context," Mr. Tanguay stated.

"Today, we can look to the future with confidence because we have the necessary funds to finance our business plan without having to tap capital markets. It goes without saying that caution will be our watchword when choosing investments and managing our portfolio," Mr. Tanguay concluded.

About Theratechnologies
Theratechnologies is a Canadian biopharmaceutical company that discovers innovative drug candidates in order to develop them and bring them to market. The Company targets unmet medical needs in specialty markets. Its most advanced compound, tesamorelin, is an analogue of the growth hormone releasing factor.  In 2008, Theratechnologies completed a confirmatory Phase 3 clinical trial evaluating tesamorelin in treating excess abdominal fat in HIV patients with lipodystrophy, a serious metabolic disorder. The Company also has other projects at earlier stages of development.

Forward-Looking Information
This press release contains information or statements that are considered "forward-looking information" within the meaning of applicable securities legislation. This forward-looking information includes, in particular, information on the approval of tesamorelin as a therapeutic product, the beneficial nature of tesamorelin for patients, the commercialization of tesamorelin and its success for the treatment of HIV-associated lipodystrophy, the submission of an NDA to the FDA by the end of the month of June 2009 and the financial autonomy of the Company. Words such as "will", "may", "could", "should", "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or the negatives of these terms or variations of them and the use of the future or conditional tense as well as similar expressions denote forward-looking information.

Forward-looking information is based upon a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company's control, which could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These risks and uncertainties include, in particular, difficulties, regulatory or otherwise, which the Company may face for submission of an NDA to the FDA, the risk that the Company may not obtain all required approvals from the FDA to market its products, the risk that the Company's products may not be accepted by the market, delays or cost overruns that could result from the use of third-party suppliers and a change in the Company's business plan that requires additional funds. 

Although the forward-looking information is based upon what the Company believes are reasonable assumptions, certain assumptions used in these forward looking statements and in the Company's anticipated objectives take into consideration that the Company will have access to all the data and necessary resources to submit an NDA to the FDA by the end of June 2009, that the FDA will approve the commercialization of tesamorelin for HIV-associated lipodystrophy in the United States, that the market will accept tesamorelin, that no major side effect will occur and that the Company's business plan will not be substantially modified, such that it could necessitate a need for additional funds.

Consequently, the forward-looking information is qualified by the foregoing cautionary statements, and there can be no guarantee that the results or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequences or effects on the Company, its business, its financial condition or its results of operation. Furthermore, the forward-looking information reflects current expectations regarding future events only as of the date of release of this press release.

Investors are referred to the Company's public filings available at http://www.sedar.com/. In particular, further details and descriptions of these risks and other factors are disclosed in the "Risk and Uncertainties" section of the Company's Annual Information Form, dated February 24, 2009, for the year ended November 30, 2008. The Company does not undertake to update or amend such forward-looking information whether as a result of new information, future events or otherwise, except as may be required by applicable law.

• Completed Phase 3 clinical trials in lipodystrophy
• Entered into a collaboration and licensing agreement with EMD Serono
• Agreement with Massachusetts General Hospital for an exploratory Phase 2 clinical trial evaluating tesamorelin
• Balance sheet strengthened through two financial transactions